These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 9625166)

  • 1. Changes at FDA may speed drug approval process and increase off-label use.
    Reh M
    J Natl Cancer Inst; 1998 Jun; 90(11):805-7. PubMed ID: 9625166
    [No Abstract]   [Full Text] [Related]  

  • 2. Off-label or off-limits?
    Ratner M; Gura T
    Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA proposes mechanism for disseminating information about off-label uses.
    Am J Health Syst Pharm; 1998 Jul; 55(14):1449-50. PubMed ID: 9676288
    [No Abstract]   [Full Text] [Related]  

  • 4. Off-label and unlicensed prescribing for children: have we made any progress?
    Waller DG
    Br J Clin Pharmacol; 2007 Jul; 64(1):1-2. PubMed ID: 17577389
    [No Abstract]   [Full Text] [Related]  

  • 5. Merck's statin first to receive over-the-counter status.
    Sheridan C
    Nat Rev Drug Discov; 2004 Jul; 3(7):542-3. PubMed ID: 15272493
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA targets unapproved drugs.
    Young D
    Am J Health Syst Pharm; 2007 Feb; 64(4):347-8. PubMed ID: 17299170
    [No Abstract]   [Full Text] [Related]  

  • 7. Marketing off-label uses to physicians: FDA's draft (mis)guidance.
    Gass A; Wilson J
    Am J Bioeth; 2008 Mar; 8(3):1-3. PubMed ID: 18570084
    [No Abstract]   [Full Text] [Related]  

  • 8. [European drug policy: welcomed modernization but shortage of political proposals concerning industry and research].
    Alván G
    Lakartidningen; 2003 Oct; 100(44):3541-2. PubMed ID: 14651017
    [No Abstract]   [Full Text] [Related]  

  • 9. The limits of free speech.
    Nature; 2012 Dec; 492(7429):311. PubMed ID: 23281497
    [No Abstract]   [Full Text] [Related]  

  • 10. Regulation of pharmacoeconomics and outcomes research.
    Radensky P
    Value Health; 2001; 4(1):12-5. PubMed ID: 11704968
    [No Abstract]   [Full Text] [Related]  

  • 11. Cautious welcome for FDA pharmacogenomics guidance.
    Katsnelson A;
    Nat Biotechnol; 2005 May; 23(5):510. PubMed ID: 15877053
    [No Abstract]   [Full Text] [Related]  

  • 12. Stoning a dead bird: advertising limits on approved new drugs.
    Strobos J
    Food Drug Law J; 1995; 50(4):533-51. PubMed ID: 10343018
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA under pressure to relax drug rules.
    Ledford H
    Nature; 2012 Dec; 492(7427):19. PubMed ID: 23222585
    [No Abstract]   [Full Text] [Related]  

  • 14. Pediatric Exclusivity and Regulatory Authority: Implications of Amgen v HHS.
    Kim J; Ross JS; Kapczynski A
    JAMA; 2018 Jan; 319(1):21-22. PubMed ID: 29117365
    [No Abstract]   [Full Text] [Related]  

  • 15. Off-label marketing and the First Amendment.
    Boumil MM
    N Engl J Med; 2013 Jan; 368(2):103-5. PubMed ID: 23234470
    [No Abstract]   [Full Text] [Related]  

  • 16. America's other drug problem: how the drug industry distorts medicine and politics.
    Relman AS; Angell M
    New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmaceuticals and medical devices: FDA oversight.
    Berry MD
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
    [No Abstract]   [Full Text] [Related]  

  • 19. Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder.
    Chace MJ; Zhang F; Fullerton CA; Huskamp HA; Gilden D; Soumerai SB
    J Clin Psychiatry; 2012 Nov; 73(11):1388-94. PubMed ID: 23146199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug marketing exclusivity under United States and European Union law.
    Junod V
    Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.